KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Other Operating Expenses (2016 - 2025)

Fulgent Genetics' Other Operating Expenses history spans 11 years, with the latest figure at $13.0 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 12.78% year-over-year to $13.0 million; the TTM value through Dec 2025 reached $31.2 million, up 67.39%, while the annual FY2025 figure was $51.4 million, 16.27% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $13.0 million at Fulgent Genetics, up from -$6.5 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $132.7 million in Q4 2023 and bottomed at -$23.9 million in Q4 2022.
  • The 5-year median for Other Operating Expenses is $11.3 million (2024), against an average of $20.3 million.
  • The largest annual shift saw Other Operating Expenses skyrocketed 2454.33% in 2021 before it tumbled 219.13% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $89.7 million in 2021, then tumbled by 126.67% to -$23.9 million in 2022, then surged by 654.87% to $132.7 million in 2023, then tumbled by 91.31% to $11.5 million in 2024, then grew by 12.78% to $13.0 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Other Operating Expenses are $13.0 million (Q4 2025), -$6.5 million (Q3 2025), and $14.3 million (Q2 2025).